An investigational once-weekly peptide that activates both the GLP-1 and glucagon receptors, studied for obesity and metabolic liver disease (MASH).
Mechanism under study
As a dual GLP-1/glucagon receptor agonist, it is proposed to combine the appetite- and glucose-related effects of GLP-1 with the energy-expenditure and hepatic effects attributed to glucagon-receptor activation.
Research-reported dosing
Investigational. Phase 2 obesity trials escalated once-weekly subcutaneous doses up to roughly 4.8 mg, and it has also been studied in MASH. Not approved.
10 mg vial + 2 mL bacteriostatic water = 5000 mcg/mL.
A 2 mg dose ≈ 40 units (50 mcg per unit).
Open this mix in the calculator →Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
Survodutide FAQ
What is Survodutide?
An investigational once-weekly peptide that activates both the GLP-1 and glucagon receptors, studied for obesity and metabolic liver disease (MASH).
What is the half-life of Survodutide?
Long — consistent with the once-weekly subcutaneous dosing used in trials.
What is the research-reported dosing for Survodutide?
Investigational. Phase 2 obesity trials escalated once-weekly subcutaneous doses up to roughly 4.8 mg, and it has also been studied in MASH. Not approved.
How is Survodutide reconstituted?
10 mg vial + 2 mL bacteriostatic water = 5000 mcg/mL.
Is Survodutide FDA-approved?
No — Survodutide is investigational and not FDA-approved. It is sold for laboratory research use only.
References
Related peptides
Mazdutide
GLP-1 / glucagon dual receptor agonist (oxyntomodulin analog)
A once-weekly GLP-1/glucagon dual receptor agonist based on the gut hormone oxyntomodulin. It has been approved in China for weight management and remains investigational in other regions.
Retatrutide
Triple GIP / GLP-1 / glucagon receptor agonist
An investigational 'triple agonist' targeting the GIP, GLP-1, and glucagon receptors. Phase-2 trials reported among the largest weight reductions seen for an incretin agent. Not approved.
Tirzepatide
Dual GIP / GLP-1 receptor agonist
A dual GIP and GLP-1 receptor agonist, FDA-approved as Mounjaro (type-2 diabetes) and Zepbound (weight management). Trials reported notably large reductions in body weight.
Semaglutide
GLP-1 receptor agonist
A long-acting GLP-1 receptor agonist, FDA-approved for type-2 diabetes and chronic weight management under brand names Ozempic, Wegovy, and Rybelsus. One of the most-studied incretin peptides.